sever
ebola
vaccin
therapeut
clinic
develop
howev
limit
knowledg
exist
qualiti
antibodi
respons
gener
differ
ebola
vaccin
studi
antibodi
repertoir
induc
vaccin
transchromosom
bovin
tcb
ebola
viru
ebov
glycoprotein
gp
recombin
gp
rgp
encod
either
deoxyribonucl
acid
dna
nanoparticlebas
vaccin
platform
analyz
use
ebov
genom
fragment
phage
display
librari
surfac
plasmon
reson
spr
base
realtim
kinet
assay
measur
antibodi
affin
matur
nativ
partial
denatur
ebola
gp
well
gp
contain
receptor
bind
domain
lack
mucinlik
domain
immunoglobulin
igg
obtain
rgp
nanoparticlevaccin
tcb
demonstr
higher
bind
affin
compar
dnavaccin
tcbinduc
igg
nativ
rgp
rgp
nanoparticl
vaccin
gener
robust
divers
antibodi
immun
respons
nativ
ebovgp
compar
dna
vaccin
may
explain
protect
efficaci
observ
antibodi
prepar
ebola
viru
ebov
outbreak
western
africa
led
renew
effort
develop
vaccin
andor
therapeut
provid
protect
sever
ebov
diseas
evd
vaccin
candid
target
glycoprotein
gp
ebov
antigp
antibodi
demonstr
protect
evd
anim
model
sab
biotherapeut
sab
develop
transchromosom
bovin
tcb
bovin
immunoglobulin
ig
gene
knock
human
artifici
chromosom
contain
full
germlin
sequenc
human
ig
insert
allow
tcb
produc
targetspecif
fulli
human
antibodi
vaccin
anim
model
rapidli
produc
larg
quantiti
polyclon
human
igg
use
passiv
prophylaxi
pathogen
thu
reduc
risk
advers
reaction
human
recent
studi
tcb
human
igg
investig
human
clinic
trial
middl
east
respiratori
syndrom
coronaviru
mycoplasma
homini
indic
term
respect
safe
well
toler
complet
phase
clinic
trial
averag
termin
igg
elimin
halflif
day
similar
humanderiv
intraven
ig
safe
efficaci
phase
clinic
trial
treat
patient
sever
immunodefici
hypogammaglobinemia
multiyear
chronic
homini
septic
hip
polyarthr
patient
receiv
year
drug
well
toler
signific
advers
event
display
improv
clinic
paramet
decreas
mycoplasma
burden
previous
codon
optim
ebov
gp
deoxyribonucl
acid
dna
vaccin
recombin
gp
rgp
nanoparticl
vaccin
use
immun
tcb
result
product
ebov
gp
neutral
antibodi
provid
partial
protect
mice
passiv
administ
lethal
ebov
challeng
howev
better
understand
polyclon
antibodi
repertoir
antibodi
qualiti
gener
differ
vaccin
platform
critic
develop
evalu
effect
ebov
vaccin
candid
therapeut
antibodi
prepar
studi
comprehens
analysi
humor
immun
respons
induc
differ
vaccin
platform
tcb
evalu
product
fulli
human
ig
tcb
describ
previous
purifi
polyclon
human
antibodi
lot
no
gift
sab
polyclon
human
antibodi
lot
obtain
tcb
immun
time
interv
week
mg
codonoptim
plasmid
dna
encod
ebov
gp
mg
plasmid
dna
encod
sudan
ebolaviru
sudv
gp
ebovsudv
gp
intramuscular
electropor
human
polyclon
gp
antibodi
lot
product
tcb
vaccin
thrice
mgkg
rgp
nanoparticl
fulli
human
igg
induc
tcb
immun
purifi
describ
construct
genefrag
phage
display
librari
complet
ebov
gp
previous
describ
genefrag
phage
display
librari
gfpdl
construct
use
entir
ebov
gp
potenti
display
possibl
viral
protein
segment
amino
acid
fusion
protein
surfac
bacteriophag
gfpdl
pan
purifi
igg
polyclon
antibodi
incub
ultravioletkil
remov
antibodi
nonspecif
interact
phage
protein
subsequ
gfpdl
affin
select
carri
solut
protein
ag
use
mg
preadsorb
igg
previous
describ
steadyst
equilibrium
bind
dna
rgpvaccin
tcb
igg
lot
respect
monitor
use
proteon
surfac
plasmon
reson
spr
biorad
recombin
gp
residu
rgpntermin
half
contain
receptor
bind
domain
rbd
residu
express
fuse
polyhistidin
tag
cterminu
purifi
use
ninta
chromatographi
ebovgp
protein
coupl
glc
sensor
chip
amin
coupl
ph
partial
denatur
condit
reson
unit
ru
captur
htg
surfac
nativ
condit
via
tag
ru
test
flow
cell
sampl
serial
dilut
purifi
mgml
inject
flow
rate
contact
time
associ
dissoci
perform
interv
flow
rate
respons
protein
surfac
correct
respons
mock
surfac
respons
separ
bufferonli
inject
monoclon
antibodi
mab
use
neg
control
experi
antibodi
offrat
constant
describ
stabil
complex
ie
fraction
complex
decay
per
second
determin
directli
polyclon
igg
interact
rgp
use
spr
describ
calcul
use
biorad
proteon
manag
softwar
heterogen
sampl
model
previous
describ
improv
measur
offrat
constant
determin
independ
spr
run
antigen
site
peptid
synthes
use
fmoc
chemistri
conjug
biotin
carboxi
terminu
biotinyl
peptid
captur
nlc
chip
biorad
satur
antibodi
bind
evalu
spr
per
experiment
condit
describ
analyz
divers
antibodi
epitop
profil
induc
vaccin
strategi
plasma
tcb
immun
time
codon
optim
ebov
gp
dna
rgp
nanoparticl
vaccin
collect
purifi
fulli
human
igg
igg
prepar
evalu
use
highli
divers
ebov
gp
gfpdl
librari
uniqu
phage
clone
compos
gp
fragment
span
entir
gp
previous
use
analyz
human
antibodi
respons
live
vaccin
adult
gfpdl
affin
select
show
prevaccin
igg
neg
control
bound
phage
across
gp
data
shown
rgp
nanoparticl
vaccin
anim
purifi
igg
demonstr
higher
number
phage
bound
compar
dna
vaccin
anim
igg
sequenc
gp
fragment
express
elut
phage
show
high
frequenc
phage
display
peptid
map
across
head
domain
ctermin
stalk
domain
ebov
gp
figur
b
bound
phage
contain
gp
sequenc
predominantli
glycan
cap
mucinlik
domain
mld
howev
rgp
nanoparticlegener
antibodi
show
divers
antibodi
epitop
profil
dna
vaccinegener
igg
specif
recogn
epitop
map
cterminu
heptad
repeat
stalk
domain
previou
studi
identifi
antigen
regionssit
repres
gray
bar
figur
ebov
gp
induc
live
vaccin
human
ebovsudvgp
dna
rgp
nanoparticl
vaccin
tcb
induc
antibodi
identifi
addit
antigen
site
current
studi
repres
black
bar
figur
site
glycan
cap
site
locat
mld
ebovgp
frequenc
antibodi
captur
phage
clone
display
antigen
site
antibodi
evalu
antibodi
bound
previous
describ
antigen
region
ii
iii
iv
v
antigen
site
ii
letter
figur
recogn
antibodi
induc
live
vaccin
human
ebovsudv
gp
dna
vaccin
induc
higher
frequenc
antibodi
bound
primarili
antigen
site
gp
glycan
cap
mld
rgp
vaccin
induc
antibodi
predominantli
recogn
antigen
site
mld
cterminu
site
vi
taken
togeth
result
ebovgp
gfpdl
affin
select
show
rgp
nanoparticl
vaccin
induc
divers
antibodi
repertoir
dna
vaccin
antibodi
recogn
wider
rang
epitop
ebov
gp
surfac
plasmon
reson
assay
optim
analyz
polyclon
antibodi
associ
dissoci
kinet
reflect
overal
antibodi
bind
avid
previou
studi
spr
use
tag
captur
protein
htg
chip
panel
conformationdepend
gpspecif
neutral
mab
confirm
conserv
nativ
gp
structur
howev
mab
lost
bind
rgp
aminecoupl
directli
glc
chip
suggest
partial
denatur
gp
loss
conform
epitop
neg
controlpurifi
tcb
igg
show
low
reactiv
ru
mgml
total
igg
concentr
rgp
spr
rgp
nanoparticleinduc
igg
show
higher
bind
nativ
homolog
ebov
rgp
compar
dna
vaccineinduc
igg
figur
bind
antibodi
prepar
also
evalu
ntermin
half
gp
residu
contain
rbd
gprbd
lack
highli
glycosyl
mld
surfac
plasmon
reson
antibodi
analysi
show
antibodi
bind
igg
gprbd
lower
bind
complet
rgp
ectodomain
confirm
gfpdl
analysi
figur
major
antibodi
vaccin
igg
prepar
recogn
epitop
primarili
mld
igg
prepar
show
equival
antibodi
bind
level
partial
denatur
rgp
suggest
rgp
nanoparticleinduc
antibodi
recogn
conformationdepend
epitop
sensit
partial
denatur
spr
bind
assay
figur
howev
ebovsudv
dna
vaccinegener
antibodi
recogn
nonconform
linear
epitop
impact
low
phmediat
denatur
spr
assay
investig
whether
vaccin
platform
promot
differenti
antibodi
affin
matur
lead
increas
antibodi
avid
determin
offrat
constant
tcbpurifi
igg
bind
nativ
ebov
rgp
gprbd
compar
antibodi
bind
offrat
nativ
rgp
bind
partial
denatur
rgp
distinguish
bind
conform
versu
lineardenatur
epitopespecif
antibodi
igg
obtain
rgp
nanoparticl
vaccin
tcb
demonstr
higher
bind
affin
slower
dissoci
rate
constant
per
second
compar
dnavaccin
tcb
nativ
ebov
rgp
ectodomain
gprbd
figur
differ
antibodi
affin
highli
diminish
partial
denatur
rgp
use
confirm
highaffin
bind
igg
gp
nanoparticl
immun
primarili
due
conformationaldepend
epitopespecif
antibodi
wherea
dnavaccin
antibodi
higher
level
antibodi
specif
lineardenatur
epitop
ebov
gp
furthermor
spr
perform
use
antigen
site
peptid
confirm
possess
bind
antibodi
overlap
antigen
site
recogn
mab
contain
cocktail
respect
shown
figur
antibodi
preferenti
bound
site
wherea
antibodi
exhibit
higher
bind
antigen
site
peptid
strong
humor
immun
respons
vaccin
shown
decreas
diseas
sever
increas
surviv
rate
ebov
anim
challeng
studi
howev
efficaci
humor
immun
respons
vaccin
ebov
depend
vaccin
platform
anim
model
use
studi
understand
immun
correl
protect
ebov
essenti
develop
effect
vaccin
well
antibodybas
therapeut
sever
mab
polyclon
antibodi
prepar
convalesc
sera
nonhuman
primat
nhp
human
shown
variabl
efficaci
differ
ebov
anim
model
challeng
studi
exampl
mab
control
infect
small
anim
model
nhp
cocktail
mab
polyclon
antibodi
develop
increas
breadth
protect
passiv
transfer
goal
decreas
evd
sever
transchromosom
bovin
recent
develop
produc
larg
quantiti
human
igg
use
passiv
immun
variou
pathogen
includ
ebov
studi
perform
comprehens
analysi
polyclon
antibodi
respons
induc
differ
vaccin
platform
tcb
rgp
base
nanoparticl
vaccin
induc
divers
gpspecif
antibodi
repertoir
ebovsudv
dnaencod
gp
vaccin
determin
unbias
gfpdl
approach
although
vaccin
induc
similar
antibodi
epitop
profil
glycan
mld
previous
identifi
recogn
protect
mab
antibodi
induc
rgp
vaccin
recogn
antigen
site
ebov
gp
could
potenti
includ
far
unknown
protect
epitop
within
antigen
site
dna
vaccineinduc
antibodi
recogn
antigen
site
includ
epitop
protect
antibodi
wherea
rgp
vaccineinduc
antibodi
bound
antigen
site
includ
known
epitop
protect
mab
compar
amount
antibodi
site
epitop
identifi
use
gfpdl
spr
perform
respect
synthet
peptid
bind
profil
peptid
demonstr
differenti
recognit
epitop
antibodi
prepar
overlap
antigen
site
howev
neither
vaccin
gener
signific
bind
antibodi
fusion
loop
gp
recogn
antipan
ebolaviru
antibodi
dna
vaccin
contain
ebov
sudv
gpencod
sequenc
plasmid
possibl
dna
vaccin
induc
antibodi
igg
prepar
recogn
common
conserv
epitop
zair
sudan
ebov
gp
glycan
cap
region
residu
howev
dna
vaccin
induc
signific
bind
antibodi
region
high
sequenc
conserv
ebov
sudv
suggest
base
result
previou
anim
studi
antibodi
induc
vaccin
strategi
could
result
protect
sever
evd
howev
antibodi
epitop
divers
induc
dna
proteinbas
vaccin
tcb
consider
constrain
compar
antibodi
repertoir
induc
live
vaccin
adult
could
due
differ
among
vaccin
use
tcb
human
well
differ
vaccin
host
antibodi
kinet
analysi
spr
demonstr
rgpbase
nanoparticl
vaccin
induc
higher
titer
nativ
gpspecif
conformationdepend
antibodi
dna
vaccin
per
milligram
polyclon
igg
differ
antibodi
respons
quantit
also
qualit
antibodi
affin
nanoparticl
vaccin
nativ
gp
higher
compar
dna
vaccineinduc
antibodi
howev
trend
specif
affin
nativ
gp
antibodi
affin
denatur
form
gp
higher
dna
vaccineinduc
igg
compar
nanoparticl
proteinbas
vaccin
find
may
suggest
differ
process
nativ
intact
gp
nanoparticl
dnaencod
gp
express
host
cell
immun
tcb
immun
system
level
gp
expressionsecret
vivo
plasmid
dna
vaccin
easili
determin
furthermor
vaccin
platform
may
also
differ
level
helper
cell
tfollicular
helper
tfh
cell
induc
tfh
play
import
role
antibodi
affin
matur
germin
center
balbc
mice
challeng
studi
mouseadapt
ebov
strain
mice
treat
mgkg
igg
mice
treat
mgkg
igg
intraperiton
day
postchalleng
surviv
lethal
ebov
infect
greater
antibodi
epitop
divers
antibodi
affin
observ
rgp
vaccin
compar
dna
vaccin
may
explain
better
vitro
neutral
well
vivo
protect
efficaci
observ
igg
prepar
previou
mice
challeng
studi
therefor
base
find
critic
develop
appropri
assay
provid
better
indepth
understand
antibodi
respons
help
guid
develop
evalu
effect
ebola
countermeasur
includ
therapeut
vaccin
disclaim
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
content
public
necessarili
reflect
view
polici
depart
health
human
servic
mention
trade
name
commerci
product
organ
impli
endors
us
govern
